ID: ALA3935135

Max Phase: Preclinical

Molecular Formula: C21H26N4O4

Molecular Weight: 398.46

Molecule Type: Small molecule

Associated Items:

Representations

Canonical SMILES:  O=C(NC[C@@H](C(=O)NO)N1CCCCC1)c1ccc(OCc2ccncc2)cc1

Standard InChI:  InChI=1S/C21H26N4O4/c26-20(23-14-19(21(27)24-28)25-12-2-1-3-13-25)17-4-6-18(7-5-17)29-15-16-8-10-22-11-9-16/h4-11,19,28H,1-3,12-15H2,(H,23,26)(H,24,27)/t19-/m0/s1

Standard InChI Key:  ZTDRQXAWZXLROA-IBGZPJMESA-N

Associated Targets(Human)

ADAM17 3550 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Matrix metalloproteinase-1 7046 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Matrix metalloproteinase 3 3433 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Matrix metalloproteinase 9 6779 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

ADAM9 81 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

ADAM10 375 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 398.46Molecular Weight (Monoisotopic): 398.1954AlogP: 1.75#Rotatable Bonds: 8
Polar Surface Area: 103.79Molecular Species: NEUTRALHBA: 6HBD: 3
#RO5 Violations: 0HBA (Lipinski): 8HBD (Lipinski): 3#RO5 Violations (Lipinski): 0
CX Acidic pKa: 8.72CX Basic pKa: 6.31CX LogP: 1.15CX LogD: 1.09
Aromatic Rings: 2Heavy Atoms: 29QED Weighted: 0.46Np Likeness Score: -0.98

References

1.  (2016)  4-alkoxy-N-(2-hydroxycarbamoyl-2-piperidinyl-ethyl)-benzamide compounds as selective TACE-inhibitors for the treatment of inflammatory diseases, 

Source

Source(1):